Amylyx Pharmaceuticals Inc banner

Amylyx Pharmaceuticals Inc
NASDAQ:AMLX

Watchlist Manager
Amylyx Pharmaceuticals Inc Logo
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Watchlist
Price: 14.33 USD -0.35%
Market Cap: $1.6B

During the last 3 months Amylyx Pharmaceuticals Inc insiders bought 100.8k USD , and sold 5.7m USD worth of shares. The stock price has increased by 21% over this period (open performance analysis).

The last transaction was made on Mar 2, 2026 by Frates James M , who sold 114.9k USD worth of AMLX shares.

Last Transactions:
Bedrosian Camille L
$-94.2k
Frates James M
$-114.9k
Mazzariello Gina
$-99.4k
Cohen Joshua B
$-424.1k
Klee Justin B.
$-423.8k
Mazzariello Gina
$-48.4k
Mazzariello Gina
$-50.5k
Klee Justin B.
$-227.6k
Frates James M
$-52.1k
Cohen Joshua B
$-227.6k
Klee Justin B.
$-27.7k
Cohen Joshua B
$-27.3k
Cohen Joshua B
Co-Chief Executive Officer
$-1.9m
Klee Justin B.
Co-Chief Executive Officer
$-1.8m
Frates James M
$-37k
Klee Justin B.
$-85.6k
Cohen Joshua B
$-85.6k
Firestone Karen
$+100.8k
Bedrosian Camille L
$-94.4k
Frates James M
$-154.7k
Bedrosian Camille L
$-175.5k
Cohen Joshua B
$-426.5k
Mazzariello Gina
$-128.7k
Klee Justin B.
$-428k
Mazzariello Gina
$-125k
Mazzariello Gina
$-121.1k
Frates James M
$-37.8k
Bedrosian Camille L
$-43.1k
Klee Justin B.
$-74.5k
Cohen Joshua B
$-74.5k
Mazzariello Gina
$-32k
Zeiher Bernhardt G
$+37k
View All Transactions

During the last 3 months Amylyx Pharmaceuticals Inc insiders bought 100.8k USD , and sold 5.7m USD worth of shares. The stock price has increased by 21% over this period (open performance analysis).

The last transaction was made on Mar 2, 2026 by Frates James M , who sold 114.9k USD worth of AMLX shares.

Sold
0-3
months
5.7m USD
5
3-6
months
1.4m USD
5
6-9
months
246.1k USD
1
9-12
months
261.8k USD
5
Bought
0-3
months
1
100.8k USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
1
37k USD

Amylyx Pharmaceuticals Inc
Insider Trading Chart

Amylyx Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Amylyx Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Amylyx Pharmaceuticals Inc
Glance View

Market Cap
1.6B USD
Industry
Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2022-01-07. The firm is developing therapies for treatment paradigm for amyotrophic lateral sclerosis (ALS), and range of neurodegenerative diseases by keeping neurons alive. The firm is pursuing commercialization of its product candidate, AMX0035. AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO) also known as ursodoxicoltaurine. AMX0035 is designed to target the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. AMX0035 keep neurons alive under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of Alzheimer’s Disease (AD) and multiple sclerosis.

AMLX Intrinsic Value
Not Available

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett